New York regulators have charged Omnium Canna with allegedly allowing unlicensed operators to manufacture and package cannabis under its license. The “rent-a-license” case exposes serious weaknesses in the state’s track-and-trace system and highlights why compliance and risk management are critical for cannabis operators.

Massachusetts cannabis advocates are fighting to keep the state’s $1.6 billion market alive as a repeal campaign gains momentum for the 2026 ballot. The outcome could redefine legalization not only in Massachusetts but across the country — and serve as a wake-up call for cannabis operators to prepare for regulatory risk.

A new lawsuit threatens to derail Florida’s adult-use cannabis initiative by challenging up to 200,000 voter signatures. As the state’s legalization campaign faces mounting legal and political hurdles, the future of recreational cannabis in Florida hangs in the balance.

Minnesota’s new cannabis retailers are facing empty shelves as supply chain bottlenecks and regulatory backlogs slow product delivery. Here’s why the shortages are happening, what lessons other states can offer, and how businesses can prepare for long-term stability.

A new synthetic cannabinoid shows strong potential in treating cachexia — the severe weight loss associated with cancer. This breakthrough could expand medical cannabis applications and reshape how cannabinoids are used in clinical care.

A federal judge in California temporarily blocked Perris from enforcing a cannabis billboard ban, ruling that the city failed to justify its restriction under the First Amendment. The case could set an important precedent for cannabis advertising rights and free commercial speech protections.

Ohio’s governor has issued a 90-day ban on intoxicating hemp-derived products, shaking up the state’s CBD and hemp market. The move highlights the growing push to regulate all THC products equally—and what businesses must do to adapt fast.

Ohio’s Senate has approved a major overhaul of marijuana DUI laws, requiring proof of actual impairment instead of relying on residual THC levels. The reform marks a shift toward science-based policy, setting a fairer and more accurate standard for cannabis enforcement.

Investor confidence is rising again as Canaccord Genuity turns bullish on U.S. cannabis stocks, citing optimism over rescheduling and federal reform. Here’s why this shift matters for operators, investors, and the broader cannabis industry.

Germany’s government has approved new restrictions on online cannabis prescriptions and deliveries, aiming to curb a surge in imports after legalization. The move reflects growing regulatory oversight in global cannabis markets and signals a new phase of compliance-driven expansion.